It was billed as a transformative deal that would drive a transformative company. And it happened just two years ago. Founded in 2003, Sublimity Therapeutics, a Dublin drug development company, had already raised around €38 million to finance the advancement of a treatment for ulcerative colitis. Then in May 2018, the company announced that it was raising a further €55 million from a host of heavy-hitting investors. It was, according to Anthony J Giovinazzo, an industry veteran installed as executive chairman at the time of the 2018 deal, an “important milestone” for the company, which was previously known as Sigmoid…

Join The Currency

INTRODUCTORY OFFER.

Sign up today: Full annual membership for just €200.

Don’t miss out on what is going on with our daily unique stories from our team of skilled journalists and insightful commentators.

Members of The Currency get full access to over 3,200 exclusive interviews, investigations, and analysis, plus over 220 podcasts.

Annual membership is just €200 for the first year, a saving of €100.

Or try The Currency for the first month for a special introductory rate of €5, a saving of €20.

Cancel at any time.

To become a member today click here.